CA9 and neoplasm: In contrast, the administration of the anti-angiogenic tyrosine kinase inhibitor, sunitinib, significantly reduces primary tumor growth, but results in exacerbation of tumor hypoxia and increased CAIX expression by tumor cells, culminating in increased metastasis.